U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H48N6O5S2
Molecular Weight 720.944
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RITONAVIR

SMILES

CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/norvir-drug.htm https://www.drugs.com/mtm/ritonavir.html http://www.wikidoc.org/index.php/Ritonavir

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Known to be CNS penetrant in guinea pig and rats. Human data not available.

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 2.2 µM [IC50]
Inhibitor
8297
 0.14 µM [IC50]
Inhibitor
8297
 0.01 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
NORVIR

Approved Use

KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14)

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
129 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Disc. AE: Death fetal...
AEs leading to
discontinuation/dose reduction:
Death fetal (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (grade 2, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Other AEs: Gastrointestinal disorder NOS, Lipids abnormal...
Other AEs:
Gastrointestinal disorder NOS
Lipids abnormal
Insulin resistance
Lipoatrophy
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
AEs

AEs

AESignificanceDosePopulation
Death fetal 1 patient
Disc. AE
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Hypertension grade 2, 1 patient
Disc. AE
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Gastrointestinal disorder NOS
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Insulin resistance
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipids abnormal
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipoatrophy
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
inducer
389

inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A
214

P-gp
1461

CYP2C19
1478

CYP2E1
882

CYP1A2
1524
CYP3A
191

CYP2D
1

CYP3A5
395
CYP3A
129

CYP1A2
701

CYP2C19
293

CYP2B6
547

UGT
29

P-gp
257
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2E1
970
 no
CYP2D6
1891
 yes [IC50 17.3 uM]
yes (co-administration study)
Comment: A published trial (Aarnoutse et al 2005) cited previously published data that reported a 145% increase in desipramine with ritonavir 500 mg twice daily dosing.
Page: 2.0
CYP2C19
1553
 yes [IC50 23.5 uM]
CYP2C9
1819
 yes [IC50 6.2 uM]
CYP1A2
1692
 yes
CYP2B6
1001
 yes
CYP2C19
1553
 yes
CYP2C9
1819
 yes
CYP3A
298
 yes
CYP3A
298
 yes
P-gp
1650
 yes
P-gp
1650
 yes
UGT
59
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A
191
 major
CYP3A4
1737
 yes [Km 0.05 uM]
CYP3A5
395
 yes [Km 0.21 uM]
CYP2D
1
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:45409
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45409
ChemicalBook
CB0119429
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0119429
MolPort
MolPort-000-883-877
https://www.molport.com/shop/molecule-link/MolPort-000-883-877
Selleck Chemicals
Ritonavir
http://www.selleckchem.com/products/Ritonavir.html
ZINC
ZINC000003944422
http://zinc15.docking.org/substances/ZINC000003944422
eMolecules
877483
https://www.emolecules.com/cgi-bin/more?vid=877483
PubMed

PubMed

TitleDatePubMed
Decreased methadone effect after ritonavir initiation.
2000 Jan
In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.
2000 Jan 7
In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.
2000 May
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
2000 May
Inhibition of HIV-1 protease by a boron-modified polypeptide.
2000 Oct 1
Saquinavir soft gelatin capsule: a comparative safety review.
2001
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.
2001
Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
2001 Apr
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
2001 Apr
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.
2001 Apr
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.
2001 Apr 1
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
2001 Apr 10
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
2001 Apr 13
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
2001 Apr 15
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].
2001 Apr 2
Antiviral drugs: current state of the art.
2001 Aug
Pharmacology and clinical experience with saquinavir.
2001 Feb
Use of HIV protease inhibitors as pharmacoenhancers.
2001 Feb
Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.
2001 Feb
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
2001 Feb
Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.
2001 Feb
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
2001 Feb
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
2001 Feb
Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
2001 Feb 15
Ritonavir-induced carbamazepine toxicity.
2001 Jan
Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
2001 Jan
Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
2001 Jan 1
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
2001 Jan 20
Lopinavir/ritonavir: a protease inhibitor combination.
2001 Jan 8
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.
2001 Jan-Feb
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
2001 Jul
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
2001 Jun
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
2001 Jun
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
2001 Jun 1
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.
2001 Jun 15
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
2001 Jun 15
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
2001 Jun 15
The safety and antiviral effect of protease inhibitors in children.
2001 Mar
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
2001 Mar
Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.
2001 Mar 1
[HIV: a guide on management of seropositive patients].
2001 Mar 3
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.
2001 Mar 30
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
2001 Mar 9
Lopinavir/ritonavir.
2001 Mar-Apr
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
2001 May
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
2001 May 25
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
2001 May 25
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
2001 May 25
[Effective in HIV: dual combination with indinavir and ritonavir].
2001 May 4
Patents

Patents

JP2000515555A
7
JP2001187746A
9
JP2001527517A
8
JP2002503670A
14
JP2002520410A
1
JP2002533470A
11
JP2002536435A
14
JP2002538171A
7
JP2002539246A
18
JP2002544210A
89
JP2003502309A
18
JP2003524620A
19
JP2003528821A
36
JP2003530310A
7
JP2004346077A
7
JP2006511554A
19
JP2006512339A
22
JP2006514917A
60
JP2006515281A
7
JP2006520756A
15
JP2007291131A
1
JP2007503428A
35
JP2007504251A
1
JP2007516260A
16
JP2007519640A
1
JP2007524616A
12
JP2007524644A
48
JP2007536237A
19
JP2008500265A
6
JP2008509742A
27
JP2008510795A
76
JP2009502882A
1
JP2009525265A
19
JP2009531441A
18
JP2010270135A
1
JP2010522142A
15
JP2010536837A
4
JP2011126898A
1
JP2011225524A
1
JP2011506339A
7
JP2011508747A
61
JP2011508748A
29
JP2011508764A
18
JP2011510926A
1
JP2011510927A
1
JP2011528275A
455
JP2011528319A
7
JP2011529864A
7
JP2012500788A
1
JP3592337B2
7
JP4413427B2
14

Sample Use Guides

In Vivo Use Guide
600 mg twice-day with meals. Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily.
Route of Administration: Oral
In Vitro Use Guide
Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.
Name Type Language
RITONAVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
NORVIR
Brand Name English
RITONAVIR [VANDF]
Common Name English
RITONAVIR [MI]
Common Name English
VIRITON
Brand Name English
EMPETUS
Brand Name English
PAXLOVID COMPONENT RITONAVIR
Brand Name English
ritonavir [INN]
Common Name English
ABBOTT-84538
Code English
VIEKIRAX COMPONENT RITONAVIR
Brand Name English
RITOVIR
Brand Name English
KALETRA COMPONENT RITONAVIR
Common Name English
RITONAVIR [HSDB]
Common Name English
RITONAVIR [USP-RS]
Common Name English
NSC-693184
Code English
ABT-538
Code English
RITONAVIR COMPONENT OF PAXLOVID
Brand Name English
RITONAVIR COMPONENT OF VIEKIRAX
Brand Name English
RTV
Common Name English
RITONAVIR [EMA EPAR]
Common Name English
RITONAVIR [JAN]
Common Name English
Ritonavir [WHO-DD]
Common Name English
RITONAVIR COMPONENT OF KALETRA
Common Name English
RITONAVIR [ORANGE BOOK]
Common Name English
RITONAVIRUM [WHO-IP LATIN]
Common Name English
A-84538
Code English
RITOMUNE
Brand Name English
RITONAVIR RELATED COMPOUNDS MIXTURE
USP-RS  
Common Name English
2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-
Systematic Name English
RITONAVIR [MART.]
Common Name English
2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-
Common Name English
RITONAVIR [USP IMPURITY]
Common Name English
RITONAVIR [USP MONOGRAPH]
Common Name English
RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]
Common Name English
RITONAVIR [WHO-IP]
Common Name English
VIEKIRAX
Brand Name English
5-Thiazolylmethyl [(αS)-α-[(1S,3S)-1-hydroxy-3-[(2S)-2-[3-[(2-isopropyl-4-thiazolyl)methyl]-3-methylureido]-3-methylbutyramido]-4-phenylbutyl]phenethyl]carbamate
Common Name English
RITONAVIR [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548747
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AR10
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AE03
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-VATC QJ05AE03
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-VATC QJ05AR10
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AP52
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
EMA ASSESSMENT REPORTS LOPINAVIR (AUHTORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AX66
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
FDA ORPHAN DRUG 549816
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
NCI_THESAURUS C97366
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
FDA ORPHAN DRUG 509215
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
EMA ASSESSMENT REPORTS KALETRA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LPV/R)
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AR23
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AP53
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
NDF-RT N0000191001
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
NDF-RT N0000175889
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
FDA ORPHAN DRUG 484715
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
NDF-RT N0000000246
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
EMA ASSESSMENT REPORTS VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
WHO-ATC J05AX67
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
EMA ASSESSMENT REPORTS NORVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
RITONAVIR
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water, freely soluble in methanol R, sparingly soluble in acetone R and very slightly soluble in acetonitrile R. Category: Antiretroviral (Protease Inhibitor). Storage: Ritonavir should be kept in a well-closed container, protected from light. Additional information: Ritonavir may exhibit polymorphism. Requirements: Ritonavir contains not less than 98.5 % and not more than 101.0 % of C37H48N6O5S2, calculated with reference to the dried substance.
FDA UNII
O3J8G9O825
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
ChEMBL
CHEMBL163
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
RS_ITEM_NUM
1604803
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
INN
7449
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
EVMPD
SUB10342MIG
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
WIKIPEDIA
RITONAVIR
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
RXCUI
85762
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY RxNorm
NDF-RT
N0000182137
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
NDF-RT
N0000182141
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
NDF-RT
N0000187064
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
DRUG BANK
DB00503
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
MESH
D019438
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
LACTMED
Ritonavir
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NDF-RT
N0000185607
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
DRUG CENTRAL
2391
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NDF-RT
N0000191266
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 1A2 Inducers [MoA]
SMS_ID
100000089167
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NDF-RT
N0000190113
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
CHEBI
45409
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NDF-RT
N0000185507
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
EPA CompTox
DTXSID1048627
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NDF-RT
N0000190117
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY UDP Glucuronosyltransferases Inducers [MoA]
NDF-RT
N0000190118
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 3A Inducers [MoA]
NSC
693184
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
DAILYMED
O3J8G9O825
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
MERCK INDEX
m9636
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Merck Index
NDF-RT
N0000190114
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
PUBCHEM
392622
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
HSDB
7160
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
IUPHAR
8804
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NCI_THESAURUS
C1609
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
CAS
155213-67-5
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
USAN
GG-103
Created by admin on Fri Dec 15 15:29:49 GMT 2023 , Edited by admin on Fri Dec 15 15:29:49 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of RITONAVIR
METABOLITE ACTIVE (PARENT)
Structure of HYDROXYRITONAVIR
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966